Review anchor
Receptor-interacting serine/threonine-protein kinase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Receptor-interacting serine/threonine-protein kinase 1
CHEMBL5464
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Receptor-interacting serine/threonine-protein kinase 1 as ChEMBL target CHEMBL5464, mapped to UniProt Q13546. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL5464
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13546
Receptor-interacting serine/threonine-protein kinase 1
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Receptor-interacting serine/threonine-protein kinase 1 matters
Receptor-interacting serine/threonine-protein kinase 1 is reviewed as Receptor-interacting serine/threonine-protein kinase 1 (UniProt Q13546); Receptor-interacting serine/threonine-protein kinase 1 shows clinical signal disease relevance led by psoriasis. 4 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 14 approved drugs, 4904 compounds, and 371 assays, with lead potency reaching pChEMBL 10.3.
Protein context
Receptor-interacting serine/threonine-protein kinase 1
Receptor-interacting serine/threonine-protein kinase 1 Sequence length is 671 aa.
Review this target as Receptor-interacting serine/threonine-protein kinase 1, mapped to UniProt Q13546. Sequence length is 671 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q13546
Protein
Disease context
psoriasis
Receptor-interacting serine/threonine-protein kinase 1 shows clinical signal disease relevance led by psoriasis. 4 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 4 additional disease programs remain visible in the same card. Linked drugs include GSK2982772.
Start review with psoriasis because it currently carries clinical signal support. Linked drugs include GSK2982772. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Clinical signal
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 14 approved drugs, 4904 compounds, and 371 assays for this target. The dominant activity type is IC50. CHEMBL4067372 is the current potency anchor at pChEMBL 10.3.
Use CHEMBL4067372 as the tractability anchor when discussing potency (pChEMBL 10.3).
Activity source · ChEMBL 36 via Core Engine
14 approved
pChEMBL 10.3
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Receptor-interacting serine/threonine-protein kinase 1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q13546, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why psoriasis is currently treated as clinical signal support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
4904
Total Compounds
371
Total Assays
14
Approved Drugs
IC50: 4966.0, KI: 841.0, EC50: 126.0, KD: 274.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4067372
|
10.3 | IC50 | — |
|
|
No preferred name
CHEMBL3785745
|
10.2 | IC50 | — |
|
|
No preferred name
CHEMBL4093220
|
10.1 | IC50 | — |
|
|
No preferred name
CHEMBL3786997
|
9.7 | IC50 | — |
|
|
No preferred name
CHEMBL5177284
|
9.6 | Kd | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
QUIZARTINIB
CHEMBL576982
|
2023 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
PONATINIB
CHEMBL1171837
|
2012 |
|
|
CRIZOTINIB
CHEMBL601719
|
2011 |
|
|
PAZOPANIB
CHEMBL477772
|
2009 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
Source Header